Pfizer and BioNTech announced on April 14 that they will seek emergency use authorisation from the US Food and Drug Administration (FDA) for a booster for their COVID-19 vaccine for children aged 5 to 11 years old. According to the firms, the proposal will be based on data from a Phase 2/3 clinical trial that indicated an increase in antibodies from a booster dose. Approximately six months following the second dose, a booster was given to 140 children in the trial. The primary series consists of two doses. One month after receiving the booster, the children had a 6-fold increase in antibodies against the Wuhan strain of SARS-CoV-2, according to the businesses. A 36-fold rise in neutralizing antibody titers was discovered in a subanalysis of 30 subjects. The trial also yielded “no new safety indications,” according to the report. The … Continue reading Pfizer Requesting To Authorize Booster Doses For Children Age 5-11.